Publikationen - Institut für Radiopharmazeutische Krebsforschung

63 Publikationen

2024

64Cu tumor labeling with hexadentate picolinic acid-based bispidine immunoconjugates

Kubeil, M.; Neuber, C.; Starke, M.; Arndt, C.; Rodrigues Loureiro, L. R.; et al. (11 authors)

RevCAR-expressing immune effector cells for targeting of Fn14-positive glioblastoma

Abdelfatah Saleh Hassan, H. A.; Mitwasi, N.; Rodrigues Loureiro, L. R.; Kegler, A.; Elizabeth González Soto, K.; et al. (11 authors)

Bone marrow-derived mesenchymal stromal cells obstruct AML-targeting CD8+ clonal effector and CAR T cell function while promoting a senescence-associated phenotype

Towers, R.; Trombello, L.; Fusenig, M.; Tunger, A.; Baumann, A.-L.; et al. (16 authors)

2023

Targeting colorectal cancer cells using AND-gated Adaptor RevCAR T-cells

González Soto, K. E.; Rodrigues Loureiro, L. R.; Bartsch, T.; Arndt, C.; Kegler, A.; et al. (16 authors)

Immunotheranostic target modules for imaging and navigation of UniCAR T-cells to strike FAP-expressing cells and the tumor microenvironment

Rodrigues Loureiro, L. R.; Hoffmann, L.; Neuber, C.; Rupp, L.; Arndt, C.; et al. (12 authors)

A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells

Kegler, A.; Drewitz, L.; Arndt, C.; Daglar, C.; Rodrigues Loureiro, L. R.; et al. (27 authors)

FLT3-directed UniCAR T-cell therapy of Acute Myeloid Leukaemia

Peschke, J.; Bergmann, R.; Mehnert, M.; González Soto, K. E.; Rodrigues Loureiro, L. R.; et al. (16 authors)

Design and Biological Evaluation of Small-Molecule PET-Tracers for Imaging of Programmed Death Ligand 1

Krutzek, F.; Donat, C.; Ullrich, M.; Zarschler, K.; Ludik, M.-C.; et al. (9 authors)

Preclinical Characterization of the 177Lu-Labeled Prostate Stem Cell Antigen (PSCA)-Specific Monoclonal Antibody 7F5

Striese, F.; Neuber, C.; Gräßel, S.; Arndt, C.; Ullrich, M.; et al. (13 authors)

Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers

Pfeifer Serrahima, J.; Zhang, C.; Oberoi, P.; Bodden, M.; Röder, J.; et al. (13 authors)

Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells

Abdelfatah Saleh Hassan, H. A.; Mitwasi, N.; Ullrich, M.; Kubeil, M.; Toussaint, M.; et al. (17 authors)

Impedimetric Nanobiosensor for the Detection of SARS-CoV-2 Antigens and Antibodies

Sandoval Bojorquez, D. I.; Janićijević, Ž.; Palestina Romero, B.; Oliveros Mata, E. S.; Laube, M.; et al. (14 authors)

Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy

Arndt, C.; Tunger, A.; Wehner, R.; Rothe, R.; Kourtellari, E.; et al. (16 authors)

2022

Clinical Significance of Tumor-Infiltrating Conventional and Plasmacytoid Dendritic Cells in Pancreatic Ductal Adenocarcinoma

Plesca, I.; Benešová, I.; Beer, C.; Sommer, U.; Müller, L.; et al. (15 authors)

Nanochips assisted peptide screening for clinical development of CAR-T cell immunotherapy

Anh Nguyen-Le, T.; Bartsch, T.; Wodtke, R.; Brandt, F.; Arndt, C.; et al. (18 authors)

Combining Radiation- with Immunotherapy in Prostate Cancer: Influence of Radiation on T cells

Lindner, D.; Arndt, C.; Loureiro, L. R.; Feldmann, A.; Kegler, A.; et al. (11 authors)

Targeting CD10 on B-Cell Leukemia Using the Universal CAR T-Cell Platform (UniCAR)

Mitwasi, N.; Arndt, C.; Loureiro, L. R.; Kegler, A.; Fasslrinner, F.; et al. (11 authors)

Development and functional characterization of a versatile radio-/immunotheranostic tool for prostate cancer management

Arndt, C.; Bergmann, R.; Striese, F.; Merkel, K.; Máthé, D.; et al. (21 authors)

Validation of CD98hc as a therapeutic target for a combination of radiation and immunotherapies in head and neck squamous cell carcinoma

Köseer, A. S.; Loureiro, L. R.; Jureczek, J.; Mitwasi, N.; González Soto, K. E.; et al. (14 authors)

2021

A Small Step, a Giant Leap: Somatic Hypermutation of a Single Amino Acid Leads to Anti-La Autoreactivity

Bartsch, T.; Arndt, C.; Loureiro, L. R.; Kegler, A.; Puentes-Cala, E.; et al. (10 authors)

Targeting acute myeloid leukemia using the RevCAR platform: a programmable, switchable and combinatorial strategy

Kittel-Boselli, E.; González Soto, K. E.; Loureiro, L. R.; Hoffmann, A.; Bergmann, R.; et al. (16 authors)

And yet it moves: Oxidation of the Nuclear Autoantigen La/SS-B is the Driving Force for Nucleo-Cytoplasmic Shuttling

Berndt, N.; Bippes, C. C.; Michalk, I.; Bartsch, T.; Arndt, C.; et al. (20 authors)

Two Be or Not Two Be: The Nuclear Autoantigen La/SS-B Is able to form Dimers and Oligomers in a Redox Dependent Manner

Berndt, N.; Bippes, C. C.; Michalk, I.; Bachmann, D.; Bachmann, J.; et al. (21 authors)

T Cell Mediated Conversion of a Non-anti-La Reactive B cell to an Autoreactive anti-La B Cell by Somatic Hypermutation

Bachmann, M.; Bartsch, T.; Bippes, C. C.; Bachmann, D.; Puentes-Cala, E.; et al. (20 authors)

Highly sensitive silicon nanowire biosensor devices for the investigation of UniCAR platform in immunotherapy

Nguyen Le, T. A.; Sandoval Bojorquez, D. I.; Arnau, P. R.; Bergoi, I.; Feldmann, A.; et al. (8 authors)

2020

Nanocytometer for smart analysis of peripheral blood and acute myeloid leukemia: a pilot study

Schütt, J.; Sandoval Bojorquez, D. I.; Avitabile, E.; Oliveros Mata, E. S.; Milyukov, G.; et al. (17 authors)

Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia

Loff, S.; Dietrich, J.; Meyer, J.-E.; Riewaldt, J.; Spehr, J.; et al. (14 authors)

Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy

Feldmann, A.; Hoffmann, A.; Bergmann, R.; Koristka, S.; Berndt, N.; et al. (13 authors)

Adaptor CAR platforms - next generation of T cell-based cancer immunotherapy

Arndt, C.; Fasslrinner, F.; Loureiro, L. R.; Koristka, S.; Feldmann, A.; et al. (6 authors)

Highly efficient targeting of EGFR-expressing tumor cells with UniCAR T cells via target modules based on Cetuximab®

Jureczek, J.; Feldmann, A.; Bergmann, R.; Arndt, C.; Berndt, N.; et al. (12 authors)

Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers

Loureiro, L. R.; Feldmann, A.; Bergmann, R.; Koristka, S.; Berndt, N.; et al. (11 authors)

UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells

Arndt, C.; Loureiro, L. R.; Feldmann, A.; Jureczek, J.; Bergmann, R.; et al. (22 authors)

“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells

Mitwasi, N.; Feldmann, A.; Arndt, C.; Koristka, S.; Berndt, N.; et al. (24 authors)

2019

Conventional CARs versus modular CARs

Feldmann, A.; Arndt, C.; Koristka, S.; Berndt, N.; Bergmann, R.; et al. (6 authors)

A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR

Arndt, C.; Feldmann, A.; Koristka, S.; Schäfer, M.; Bergmann, R.; et al. (19 authors)

Theranostic CAR T cell targeting: A brief review

Arndt, C.; Bachmann, M.; Bergmann, R.; Berndt, N.; Feldmann, A.; et al. (6 authors)

  • Open Access Logo Journal of Labelled Compounds and Radiopharmaceuticals 62(2019)8, 533-540
    DOI: 10.1002/jlcr.3727

T cells engrafted with a UniCAR 28/ζ outperform UniCAR BB/ζ-transduced T cells in the face of regulatory T cell-mediated immunosuppression

Kegler, A.; Koristka, S.; Bergmann, R.; Berndt, N.; Arndt, C.; et al. (10 authors)

Midostaurin abrogates CD33-directed UniCAR and CD33-CD3 bispecific antibody therapy in acute myeloid leukemia

Fasslrinner, F.; Arndt, C.; Koristka, S.; Feldmann, A.; Altmann, H.; et al. (9 authors)

An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells

Jureczek, J.; Bergmann, R.; Berndt, N.; Koristka, S.; Kegler, A.; et al. (10 authors)

Fluorescent Mouse Pheochromocytoma Spheroids Expressing Hypoxia-Inducible Factor 2 alpha: Morphologic and Radiopharmacologic Characterization

Seifert, V.; Liers, J.; Kniess, T.; Richter, S.; Bechmann, N.; et al. (10 authors)

  • Journal of Cellular Biotechnology 5(2019)2, 135-151
    DOI: 10.3233/JCB-199005
    ISSN: 2352-3689

Tonic signaling and its effects on lymphopoiesis of CAR-armed hematopoietic stem and progenitor cells

Albert, S.; Koristka, S.; Gerbaulet, A.; Cartellieri, M.; Arndt, C.; et al. (15 authors)

Anti-CAR engineered T cells for epitope-based elimination of autologous CAR T cells

Koristka, S.; Ziller-Walter, P.; Bergmann, R.; Arndt, C.; Feldmann, A.; et al. (11 authors)

2018

Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells

Loureiro, L.; Feldmann, A.; Bergmann, R.; Koristka, S.; Berndt, N.; et al. (10 authors)

Strain-specific metastatic phenotypes in pheochromocytoma allograft mice

Ullrich, M.; Liers, J.; Peitzsch, M.; Feldmann, A.; Bergmann, R.; et al. (12 authors)

From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo

Albert, S.; Arndt, C.; Koristka, S.; Berndt, N.; Bergmann, R.; et al. (10 authors)

Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology

Koristka, S.; Kegler, A.; Bergmann, R.; Arndt, C.; Feldmann, A.; et al. (17 authors)

2017

Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model

Bejestani, E. P.; Cartellieri, M.; Bergmann, R.; Ehninger, A.; Loff, S.; et al. (17 authors)

Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells

Bachmann, D.; Aliperta, R.; Bergmann, R.; Feldmann, A.; Koristka, S.; et al. (19 authors)

Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells

Mitwasi, N.; Feldmann, A.; Bergmann, R.; Berndt, N.; Arndt, C.; et al. (17 authors)

A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform

Albert, S.; Arndt, C.; Feldmann, A.; Bergmann, R.; Bachmann, D.; et al. (18 authors)

Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”

Feldmann, A.; Arndt, C.; Bergmann, R.; Loff, S.; Cartellieri, M.; et al. (20 authors)

Cryogel-Supported Stem Cell Factory for Customized Sustained Release of Bispecific Antibodies for Cancer Immunotherapy

Aliperta, R.; Welzel, P. B.; Bergmann, R.; Freudenberg, R.; Berndt, N.; et al. (17 authors)

2016

Switching CAR T cells on and off: A novel modular platform for retargeting of T cells to AML blasts

Cartellieri, M.; Feldmann, A.; Koristka, S.; Arndt, C.; Loff, S.; et al. (10 authors)

2015

Improved Killing of AML Blasts By Dual-Targeting of CD123 and CD33 Via Unitarg a Novel Antibody-Based Modular T Cell Retargeting System

Arndt, C.; Feldmann, A.; Koristka, S.; Cartellieri, M.; von Bonin, M.; et al. (9 authors)

  • BLOOD 126(2015), 2565

Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts

Aliperta, R.; Cartellieri, M.; Feldmann, A.; Arndt, C.; Koristka, S.; et al. (12 authors)

Tregs activated by bispecific antibodies: Killers or suppressors?

Koristka, S.; Cartellieri, M.; Arndt, C.; Feldmann, A.; Seliger, B.; et al. (7 authors)

2014

Redirection of CD4+ and CD8+ T lymphocytes via a novel antibody-based modular targeting system triggers efficient killing of PSCA+ prostate tumor cells

Arndt, C.; Feldmann, A.; Töpfer, K.; Koristka, S.; Cartellieri, M.; et al. (9 authors)

Simultaneous Targeting of Prostate Stem Cell Antigen and Prostate-Specific Membrane Antigen Improves the Killing of Prostate Cancer Cells Using a Novel Modular T Cell-Retargeting System

Arndt, C.; Feldmann, A.; Koristka, S.; Cartellieri, M.; Dimmel, M.; et al. (8 authors)

A novel ex vivo Isolation and Expansion Procedure for Chimeric Antigen Receptor Engrafted Human T Cells

Cartellieri, M.; Koristka, S.; Arndt, C.; Feldmann, A.; Stamova, S.; et al. (15 authors)

Characterization of a novel single-chain bispecific antibody for retargeting of T cells to tumor cells via the TCR co-receptor CD8

Michalk, I.; Feldmann, A.; Koristka, S.; Arndt, C.; Cartellieri, M.; et al. (8 authors)

Letter to the editor: Cytotoxic response of human regulatory 1 T cells upon T cell receptor-mediated activation – a 2 matter of purity

Koristka, S.; Cartellieri, M.; Arndt, C.; Feldmann, A.; Töpfer, K.; et al. (9 authors)

TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity

Cartellieri, M.; Arndt, C.; Feldmann, A.; von Bonin, M.; Ewen, E.-M.; et al. (14 authors)

Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: Description of a novel modular targeting system

Arndt, C.; Feldmann, A.; von Bonin, M.; Cartellieri, M.; Ewen, E.-M.; et al. (14 authors)